Warner Chilcott is a global specialty pharmaceutical company currently focused on the gastroenterology, women's healthcare, dermatology and urology segments of the North American and Western European pharmaceuticals markets. Since being spun out of Warner-Lambert in 1996, Warner Chilcott has evolved, through a series of acquisitions and divestitures, from a small seller of undifferentiated products to a fully integrated pharmaceutical company with a broad portfolio of leading branded products. The acquisition of The Procter & Gamble Company's global branded pharmaceuticals business on October 30, 2009 transformed Warner Chilcott into a global pharmaceuticals company with significant scale and geographic reach. Today, Warner Chilcott has an expanded sales force and infrastructure to better promote products in the U.S., major Western European and other markets, increased diversity of revenue sources, enhanced product development capabilities and a deeper product development pipeline.

Headquartered in Ardee, Ireland, Warner Chilcott has employees in 12 countries in North America and Western Europe. The Company's manufacturing facilities are located in Puerto Rico, Northern Ireland and Germany. Warner Chilcott is listed on the Nasdaq Stock Exchange and trades under the symbol WCRX.

Currently, Warner Chilcott's marketed products are concentrated in four therapeutic categories: gastroenterology, women's health, dermatology and urology.

ASACOL^® is the leading treatment for ulcerative colitis in the U.S. market for orally administered 5-aminosalicylic acid products. The new delayed-release formulation ASACOL^® HD provides dosing advantages for patients in the treatment of moderately active ulcerative colitis.

ACTONEL^® is the leading branded product in the U.S. non-injectable osteoporosis market for the prevention and treatment of osteoporosis in women.

LOESTRIN^® 24 Fe was the first oral contraceptive featuring 24 days of active therapy compared with the traditional 21-day dosing regimen. The Company's oral contraceptive portfolio also includes FEMCON^® Fe, OVCON^® 35 and OVCON^® 50 and ESTROSTEP^® Fe.

ESTRACE^® Cream is a leading topical product for the treatment of urogenital symptoms of menopause.

FEMHRT^® is a systemic therapy for the treatment of menopausal symptoms.

DORYX^® 150 mg, a tetracycline-class oral antibiotic, is indicated for the adjunctive treatment of severe acne. DORYX is one of the leading branded oral tetracyclines in the U.S. market.

ENABLEX^® is prescribed to adults to treat the symptoms of overactive bladder. Warner Chilcott co-promotes ENABLEX under an agreement with Novartis.

The Company's internal development efforts are focused primarily on developing new products that target therapeutic areas with established regulatory guidance. Warner Chilcott seeks to leverage the experience and proven capabilities of its research and development team to make proprietary improvements to its existing products, develop new and enhanced dosage forms and bring new products to market. This group of talented professionals possesses expertise in chemistry, formulation, clinical operations, and the regulatory approval processes in the U.S. and Western Europe. Its efforts have produced a number of successful internally developed products launched during the last several years.

To supplement its organic growth, Warner Chilcott continually evaluates opportunities to expand its pharmaceutical product portfolio by reviewing potential product in-licensing, acquisition and partnership opportunities that it believes will complement its strategic focus and that may benefit from promotion by its sales force. Examples of the pursuit of this strategy include Warner Chilcott's product development relationships with Paratek Pharmaceuticals, Inc. and Dong-A PharmTech Co. Ltd.